The commercial launch in Germany is part of an exclusive licensing agreement from March 2024, allowing Norgine to market PEDMARQSI in Europe, Australia, and New Zealand. Fennec received an upfront ...
X4 Pharmaceuticals (XFOR) and Norgine announced that they have entered into an exclusive licensing and supply agreement under which Norgine will commercialize mavorixafor in Europe, Australia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback